

Early Launch of Online Men's Health Platform

12 December 2024

Highlights:

- Online telehealth platform facilitating regulated prescription of SPONTAN® has launched ahead of Q1 2025 target.
- Australian men can now access SPONTAN through the TGA's early access scheme through a strategic joint venture with Restorative Health Clinic Pty Ltd (RSHC), with bookings via rshealth.com.au.
- Platform delivers comprehensive men's health services through online telehealth consultations. Early launch driven by strong market demand and operational readiness.
- Growing proportion of Erectile Dysfunction ("ED") prescriptions going online.

LTR Pharma Limited (ASX:LTP) ("LTR Pharma", "the Company") is pleased to announce that its joint venture partner, the Restorative Health Clinic ("RHC"), has launched an online healthcare platform ahead of the previously communicated Q1 2025 timeline. The platform, operated by RSHC, delivers comprehensive men's health services through telehealth consultations.

Restorative Health Clinic Founder, Melissa Hadley Barrett, said: *"We're thrilled to launch our online booking, consultation, and prescribing platform for men's health. Our team of specialists is ready to provide evidence-based care for erectile dysfunction, combining personalised treatment with improved accessibility for Australian men."*

RSHC's early launch reflects a strong interest in accessible healthcare solutions. The platform combines RSHC's clinical expertise in men's health with access to innovative treatments, including but not limited to, LTR Pharma's SPONTAN, providing Australian men with convenient access to healthcare professionals and evidence-based treatments.

LTR Pharma Executive Chairman, Lee Rodne, said: *"This early launch by our joint venture partner demonstrates strong market demand for innovative healthcare solutions in men's health. The platform provides an additional channel for delivering treatments, including SPONTAN, to Australian men via early access scheme pathways. We look forward to working with the RHC team to support the delivery of professional healthcare services in this growing online market."*

The platform offers:

- Professional medical consultations by experts in treating erectile dysfunction
- Comprehensive therapeutic services in men's health
- Prescription and non-prescription treatments
- Integrated health management solutions provided by RHC's clinical team

*Source: Fortune Business Insights, Global Telehealth Market Report 2024-2032

-Ends-

This announcement has been approved by the Board of Directors.

About LTR Pharma

LTR Pharma is focused on improving men's health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma's lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.

For further information please contact:

Media enquiries
Haley Chartres
haley@hck.digital

Investor enquiries
Peter McLennan
investors@ltrpharma.com